Yunying Lucy Liu

Senior Research Scientist

UAMS

Also affiliated: Army Medical University (2020); University of Arkansas Medical Center (2018); University of Alabama at Birmingham (2004–2008); Xinqiao Hospital (2020); Stanford Medicine (2020–2025); UAB Medicine (2004); Institut du cancer Rosalind & Morris Goodman (2024); McGill University (2024); Stanford University (2020–2025)

10 h-index 35 pubs 657 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Y. Lucy Liu's research has focused on the genomic and molecular underpinnings of juvenile myelomonocytic leukemia (JMML). Her work has investigated the role of specific genetic mutations, such as those in SETBP1 and PTEN, in the prognosis and development of JMML. Liu has also participated in clinical trials, including a Phase II/III trial evaluating the use of a farnesyl transferase inhibitor in JMML patients prior to transplantation. Her research extends to animal models, with recent work exploring updates and challenges in animal models of Diamond-Blackfan anemia. Liu's publication record includes studies on the genomic landscape of JMML and the immune landscape of oncohistone-mutant gliomas. She has co-authored 28 publications, accumulating 558 citations and an h-index of 8. She has collaborated with Peter D. Emanuel at the University of Arkansas for Medical Sciences on shared publications.

Metrics

h-index: 10
Publications: 35
Citations: 657

Positions

Senior Research Scientist 2019–present

Stanford University School of Medicine Pediatrics/Stem Cell Transplantation and Regenerative Medicine ORCID
Senior Research Scientist publications 2008–2025

University of Arkansas for Medical Sciences ORCID

Selected Publications

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens (2025)

Blood Neoplasia DOI OpenAlex
Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age–specific mouse model (2020)

Blood Advances 5 citations DOI OpenAlex
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia (2018)

Cellular Signalling 9 citations DOI OpenAlex
The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML (2016)

Blood DOI OpenAlex
JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency (2016)

Blood 3 citations DOI OpenAlex
Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice (2016)

Endocrine Related Cancer 8 citations DOI OpenAlex
The genomic landscape of juvenile myelomonocytic leukemia (2015)

Nature Genetics 311 citations DOI OpenAlex
Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN (2014)

Blood 1 citation DOI OpenAlex
Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia (2014)

Blood 1 citation DOI OpenAlex
Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion (2014)

Blood DOI OpenAlex
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group (2014)

Pediatric Blood & Cancer 51 citations DOI OpenAlex
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia (2014)

Blood 80 citations DOI OpenAlex
Mutations in GATA2 are rare in juvenile myelomonocytic leukemia (2014)

Blood 12 citations DOI OpenAlex
Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia (2013)

Blood DOI OpenAlex
Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML) (2013)

Blood 2 citations DOI OpenAlex